MedPath

Danco Seeks FDA Approval for Mifepristone in Miscarriage Management

  • Danco Laboratories is seeking FDA approval to expand the use of mifepristone (Mifeprex) for managing miscarriages, potentially increasing access to treatment.
  • The application includes scientific data supporting mifepristone's safety and efficacy in miscarriage management, an area with existing legal challenges.
  • If approved, this could provide a non-surgical option for women experiencing miscarriages, addressing a critical need in reproductive healthcare.
  • The move comes amid ongoing debates and legal battles surrounding abortion access, highlighting the complex landscape of reproductive rights.
Danco Laboratories is preparing to seek FDA approval for its drug Mifeprex (mifepristone) to be used in the management of miscarriages. This strategic move aims to broaden the drug's availability and utility, particularly when its use in medication abortion is under legal scrutiny.
Mifepristone, already a key component in medical abortions, could offer a non-surgical alternative for women experiencing miscarriages. The company is compiling scientific data to support its application to the FDA, hoping to demonstrate the drug's safety and efficacy for this new indication.
If the FDA approves the application, mifepristone could become more widely accessible for miscarriage management, providing a crucial option for women's reproductive health. This development occurs against the backdrop of legal challenges and debates surrounding abortion access, adding complexity to the drug's potential expanded use.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Biotest Submits Fibrinogen Biologics License Application to FDA

Biotest has submitted a Biologics License Application (BLA) to the FDA for its Fibrinogen product, addressing acquired fibrinogen deficiency.

Capricor Therapeutics Completes FDA Submission for Deramiocel in DMD Cardiomyopathy

Capricor Therapeutics has completed its Biologics License Application (BLA) submission to the FDA for deramiocel to treat Duchenne muscular dystrophy (DMD) cardiomyopathy.

FDA Considers Darzalex Faspro for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson seeks FDA approval for Darzalex Faspro to treat high-risk smoldering multiple myeloma, potentially the first approved therapy for this condition.

Ifetroban Receives FDA Orphan Drug Designation for Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Ifetroban, a thromboxane-prostanoid receptor antagonist, has been granted Orphan Drug Designation by the FDA for treating cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD).

Novartis Loses Bid to Block Generic Entresto, J&J Cuts Neurology Programs

A U.S. judge ruled that the FDA can approve generic versions of Novartis' heart failure drug Entresto, which generated over $6 billion in revenue last year.

FDA's Expanded Approval of ELEVIDYS for Duchenne Muscular Dystrophy Sparks Controversy

The FDA expanded approval for delandistrogene moxeparvovec-rokl (ELEVIDYS) to include a broader range of Duchenne muscular dystrophy patients, including non-ambulatory individuals.

FDA Clears IND for Myogenica's MyoPAXon in Duchenne Muscular Dystrophy

Myogenica, a University of Minnesota startup, received FDA clearance for its IND application for MyoPAXon, a stem cell therapy for muscular regeneration.

Capricor's Deramiocel Shows Sustained Benefits in Duchenne Muscular Dystrophy

Capricor Therapeutics' deramiocel demonstrated a 47% reduction in disease progression in skeletal muscle over three years in DMD patients.

FDA Approves Santhera's Agamree (Vamorolone) for Duchenne Muscular Dystrophy

The FDA has approved Agamree (vamorolone) for treating Duchenne Muscular Dystrophy (DMD) in patients aged two years and older, offering a novel corticosteroid treatment option.

Reference News

[1]
Mifepristone Maker To Seek FDA OK For Use Of Drug To Treat Miscarriages
kffhealthnews.org · Oct 9, 2024

Danco plans to seek FDA approval for mifepristone use in managing miscarriages, potentially expanding its availability a...

[2]
Around the nation: FDA to rule if 'abortion drug' mifepristone can be used to manage miscarriages
advisory.com · Oct 21, 2024

Danco Laboratories seeks FDA approval for Mifeprix (mifepristone) to manage miscarriages.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy